Matinas BioPharma (NYSEAMERICAN:MTNB – Get Free Report) issued its earnings results on Wednesday. The company reported ($0.02) EPS for the quarter, hitting the consensus estimate of ($0.02), Zacks reports.
Matinas BioPharma Stock Performance
NYSEAMERICAN MTNB remained flat at $0.15 during trading on Thursday. The company’s stock had a trading volume of 686,970 shares, compared to its average volume of 1,147,369. Matinas BioPharma has a 12-month low of $0.12 and a 12-month high of $0.89. The firm has a market capitalization of $38.38 million, a P/E ratio of -1.28 and a beta of 1.70.
Matinas BioPharma Company Profile
Featured Stories
- Five stocks we like better than Matinas BioPharma
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Michael Burry’s Alibaba Bet and the Broader Market Implications
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Jeff Brown’s Exegesis AI Stock Picks
- Investing in Construction Stocks
- Warren Buffett’s Bet: Why Berkshire Hathaway Bought Ulta Stock
Receive News & Ratings for Matinas BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.